UPDATE 1-Roche wins wider EU label for arthritis drug

June 8 (Reuters) – Roche (ROG.VX) said on Tuesday the European Commission had extended the label for its drug Roactemra to reduce the rate of progression of joint damage and improve physical function in patients with rheumatoid arthritis, when given in combination with the older drug methotrexate.

The move had been expected following a positive recommendation from the European Medicines Agency in April.

The drug, which is known as Actemra in the United States, is currently approved for use in combination with methotrexate to treat adults with moderate to severe rheumatoid arthritis who respond inadequately to other treatments.

The new label extension is a recognition that Roactemra can also inhibit structural damage to joints, reinforcing its effectiveness.

(Writing by Ben Hirschler)

Boffins develop ”The Kug”: a kettle and a mug!

London, May 12 (ANI): A mug which doubles as a kettle and features a heating element that can boil water in just 90 seconds to make a cup of tea or coffee has been developed.

Kug is the brainchild of Ben Millett, 21, and Alan Harrison, 22, who came up with it for a design project at the National College of Art and Design in Dublin.

The pair had been tasked with creating a product to help people with rheumatoid arthritis when they created the Kug.

“As part of our research we met people with the condition to talk to them about what kind of problems they encountered on a day-to-day basis,” the Telegraph quoted Millett as saying.

“And when we stopped for lunch we noticed some of the ladies trying to pour a cup of tea. After chatting to them we found out how difficult it was for them to lift a kettle that”s how it all started.

“We looked at the whole process of making a hot drink – from the kettle to putting a tea bag in a cup and filling it with water. And after lots of concepts we ended up with this idea.

“It meant one less object people would have to deal with and it wouldn”t be such a strain on the wrists, hands and fingers,” Millett added.

The design even won the Arthritis Ireland Easy to Use Design Award.

The Kug, similar in size to a travel mug, is made up of two cups.

The outer cup contains the heating filament and is plugged into a base, which is powered through mains electricity.

The inner cup, which contains the liquid, can be removed and washed after every use.

Millett said: “It works just like an ordinary kettle.

“When the water”s boiled you just take the cup off the base and enjoy your drink. You can also adjust the temperate on the base so it keeps the liquid warm until you”re ready.

He added: “It”s energy efficient and saves water because you only put the amount you actually need into the cup. It”s also portable so you can have it at home or take it in the car with you and have it on your desk at work. And it”s much lighter than a kettle.” (ANI)

Gene discovery offers hope of screening test for bone disease

London, May 3 (ANI): An international team of scientists, led by the University of Edinburgh, has identified three genes linked to the development of Paget”s disease, a painful bone condition.

The researchers believe the genes are involved in regulating the rate at which bone is repaired, providing an explanation of why the disease might occur.

Paget”s disease disrupts the body”s normal process of breaking down old bone and replacing it. The condition leads to enlarged and malformed bones and patients can suffer from bone pain, brittle bones susceptible to fractures, and advanced arthritis.

The scientists said that identifying the genes that predispose people to the bone disease could lead to the development of a screening test to identify those most at risk, and improve access to preventative treatment.

The researchers studied the genes of 1250 patients with Paget”s disease to find the genes that could cause the condition.

The team – which included scientists from Spain, UK, New Zealand, and Australia – found that three genes that were faulty more frequently in patients with the bone disease than in healthy people.

Together, the faulty genes accounted for the development of Paget”s disease in about 70 per cent of cases.

The results confirmed that genes play a crucial role in the development of Paget”s disease, which explains why many patients have a family history of the condition.

It is hoped that the discovery will allow early detection of the disease and allow doctors to give preventative treatment before bones have become damaged.

The study has been published in the journal Nature Genetics. (ANI)

Osteoarthritis tied to unequal length of leg

Washington, Apr 1 (ANI): Arthritis in the knee is linked to the common trait of having one leg that is longer than the other, claims a new study.

Developing early strategies for treatment may be possible, believes Derek Cooke, Queen”s University adjunct professor and a co-author of the study.

“Most pediatricians adopt a ”wait and see” attitude for children with limb misalignment when they”re growing,” says Dr. Cooke. “If we can spot factors creating changes in alignment early in bone development, theoretically we could stop or slow down the progression of osteoarthritis.”

To reach the conclusion, data was collected using x-ray images from more than 3,000 adults aged 50 to 79 who either had knee pain or risk factors for knee osteoarthritis as a part of the Multi Centre Osteoarthritis Study (MOST). Subjects were reassessed after a 30-month period and the researchers found that osteoarthritic changes in the knee were most significant in individuals with pronounced (more than 1 cm) leg length inequality, the shorter leg being most affected.

Leg length inequality is difficult to detect. A small leg length differential – 1 cm or less – can be corrected with a shoe insert, while a bigger one can be corrected with surgery. But because the condition often goes undiagnosed, many people don”t realize they have a leg length differential until they”re diagnosed with osteoarthritis.

Arthritis in the knees can cause pain, swelling and stiffness, and limit mobility. (ANI)

`Invincibles’ cricketer Hamence dies at 94

Adelaide, Mar.25 (ANI): The roll of cricket”s “Invincibles” has shrunk to three with the death of Australia”s oldest Test player Ron Hamence.

Hamence, who toured England with Don Bradman”s legendary 1948 team without playing a Test, died at a nursing home in Adelaide on Wednesday night at the age of 94.

“He was a lovely man with a great sense of humour,” said Denis Brien, cricket historian and president of Hamence”s old club West Torrens.

He said Hamence suffered badly from arthritis in later life, but had nursed his wife Nora until she died four years ago, after which he became almost a recluse.

A daughter, Lynette Hallett, survives him.

Hamence, born in November 1915, when Australian soldiers were still fighting at Gallipoli, never drove a car in his life.

He was an attacking batsman who used brilliant footwork against slow bowlers.

“He once said he used to imagine that there was no wicketkeeper, and that he and the bowler were the only two in the game,” Brien told AAP.

Hamence made his debut against England in 1947 and played three Tests, with a top score of 30 not out.

He had the distinction of making a century in his first and last first-class matches for South Australia.

His death leaves Sam Loxton, 88, Arthur Morris, 88, and Neil Harvey, 81, as the only survivors of the team that toured England undefeated to mark the end of Bradman”s career. (ANI)

Turning off oncogene may inhibit lung cancer stem cells’ growth

Washington, Sep 9 (ANI): A lung cancer oncogene, called PKCiota, is necessary for the proliferation of lung cancer stem cells, and turning it off could act as a key for the treatment of this deadly disease, according to scientists at the Mayo Clinic campus in Florida.

These stem cells are rare and powerful master cells that manufacture the other cells that make up lung tumours, and are resistant to chemotherapy treatment.

The study also shows that an agent, aurothiomalate, being tested at Mayo Clinic in a phase I clinical trial substantially inhibits growth of these cancer stem cells.

“Our data indicate that PKCiota is required for the earliest steps in the development of lung cancer, which is the expansion of tumor-initiating cells or cancer stem cells,” said the study’s senior author, Dr. Alan Fields.

“Lung cancer stem cells appear to be the major drivers in many common lung cancers, and in order for a therapeutic treatment to be effective, it has to disrupt these cancer stem cells. We show that aurothiomalate, the agent now being tested in lung cancer patients, can, in fact, target these cells,” he added.

While aurothiomalate was once used to treat rheumatoid arthritis, the researchers have now discovered that it can also target PKCiota.

Currently, the agent is being tested in patients at Mayo Clinic’s sites in Minnesota and Arizona and, based on this phase I trial, a phase II human clinical trial is planned to combine aurothiomalate with agents targeted at other molecules involved in cancer growth.

“We had previously shown that PKCiota is required to maintain tumor growth, but what this study sought to determine is whether PKCiota is involved in the initial steps of lung cancer development,” said Fields.

Fields said that, in mice, an oncogene known as Kras is thought to transform normal lung stem cells into cancer stem cells, thereby initiating lung cancer.

In the present study, the researchers established a strain of mice in which Kras can be activated at the same time that the PKCiota gene is inactivated.

They found that when the PKCiota gene is inactivated, Kras was unable to cause errant growth and expansion of lung stem cells in mice, the process that initiates tumour formation.

“What this told us is that Kras requires PKCiota to transform the lung stem cells and make them proliferate. In other words, PKCiota is downstream from Kras, and is necessary for Kras to initiate lung tumor formation,” said Fields.

After discovering that aurothiomalate disables PKCiota, the researchers tested whether this agent is effective against lung cancer that develops due to Kras mutation.

“The drug showed potent inhibitory effects on the Kras-dependent proliferation of lung cancer stem cells both in cell culture and in animals,” said Fields.

“That further suggests that a drug like aurothiomalate could have an effect on tumors that are dependent on either Kras or PKCiota for growth and survival, and that is potentially a lot of cancers.

Aurothiomalate appears to be one of the few drugs available that can effectively target these critical cancer stem cells. In the clinic, however, it is likely that aurothiomalate will be most effective when combined with other agents designed to target other tumor survival pathways,” he added.

The study has been published in Cancer Research. (ANI)

Healthy lifestyle simplest, best way to cut breast cancer risk

London, Sept 1 (ANI): A healthy lifestyle, including keeping weight down, exercising for 30 minutes a day and limiting alcohol to a single drink a day, is the simplest and best way for women to cut the risk of breast cancer, says a new study.

The study by the World Cancer Research Fund (WCRF ) has found the strongest evidence yet that lifestyle is linked to the risk of developing breast cancer, reports The Times.

The research came to the conclusion after showing that more than four out of ten cases could be prevented if women exercised, limited their alcohol intake and maintained a healthy weight.

Breastfeeding also helps to reduce the risk of developing the disease, the scientists at Imperial College London said.

Arlene Wilkie, director of research and policy at Breast Cancer Campaign, said: “This review provides further evidence that maintaining a healthy weight throughout life along with regular exercise will reduce the risk of health problems such as breast cancer, heart disease, high blood pressure, diabetes and arthritis.” (ANI)

Gene behind gum disease, osteoporosis, arthritis identified

Washington, Aug 31 (ANI): An international team of researchers have identified a gene that is common in the development of gum disease, rheumatoid arthritis, and osteoporosis.

Experts at Hospital for Special Surgery say that their findings about the gene, called interferon regulator factor-8 (IRF-8), may lead to new treatments in future.

“The study doesn’t have immediate therapeutic applications, but it does open a new avenue of research that could help identify novel therapeutic approaches or interventions to treat diseases such as periodontitis, rheumatoid arthritis or osteoporosis,” said Nature magazine quoted Dr. Baohong Zhao, a research fellow in the Arthritis and Tissue Degeneration Program at Hospital for Special Surgery located in New York City, as saying.

The researchers discovered that downregulation of IRF-8 (meaning that the gene produces less IRF-8 protein) increases the production of cells called osteoclasts that are responsible for breaking down bone.

In humans and animals, bone formation and bone resorption are closely coupled processes involved in the normal remodelling of bone. Enhanced development of osteoclasts, however, can create canals and cavities that are hallmarks of diseases such as periodontitis, osteoporosis and rheumatoid arthritis.

The genome-wide study showed that the expression of IRF-8 was reduced by 75 percent in the initial phases of osteoclast development.

The genetically engineered mice deficient in IRF-8 had decreased bone mass and severe osteoporosis.

The researchers concluded that IRF-8 suppresses the production of osteoclasts.

“This is the first paper to identify that IRF-8 is a novel key inhibitory factor in osteoclastogenesis (production of osteoclasts),” said Zhao.

“We hope that the understanding of this gene can contribute to understanding the regulatory network of osteoclastogenesis and lead to new therapeutic approaches in the future,” Zhao added.

The study has been published in the journal Nature Medicine. (ANI)

New Cytotron treatment effective in treating cancer patients in Bangalore

Bangalore, Aug 28 (ANI): The new Cytotron treatment that includes use of radio frequency, high power non-ionizing, non-thermal electromagnetic waves instead of high frequency radiation has emerged as a popular therapy for cancer patients in Bangalore.

Developed by Rajah Vijay Kumar of India in 1987, the Cytotron device helps in tissue regeneration, degeneration and repair for the purposes of treating several chronic or degenerative diseases such as cancer and arthritis.

The treatment modality is non-invasive, painless and free from side effects.

Clinical test have shown that Cytotron is very effective in curing certain conditions such as a damaged knee by regenerating the cartilage tissue.

Dr. Nayar of Ojus Health Care, Bangalore, said that Cytotron treated patients have survived for a longer period than patients treated by other methods.

“When there is hardly any chance of survival after one year, those kind of patients have been taken for the clinical trials and from that we found that as against the expected 0-5 per cent may be surviving after one year. We got a very interesting and encouraging result of may be up to 50 per cent in different series. So 40-50 per cent to even may be little more per cent of people are able to survive year or more,” said Dr. Nayar.

Dr. Nayar also said that the treatment is safe and healthy cells are not affected in any way.

“This is something, which is very unique. It’s safe. It’s absolutely harmless and with this machine, we can target it to the exact depth in the body tissue,” said Dr. Nayar.

One such success story of Cytotron treatment is that of Abraham, a surgeon-cum-cancer patient.

Abraham, who is a patient of arthritis, has been undergoing the treatment for the past 15 days. He said that he has found improvement in his conditions and is now able to walk without any pain.

“I felt the difference, the swelling came down and the pain also reduced. I felt some sort of relief in that one. So the actual duration day told 21 days, so after 15 days of treatment, it’s comfortable and my all the symptoms got relieved. I am finding improvement in my condition,” said Abraham.

Doctors consider Cytotron as a useful method to treat cancer. By Shweta ANI)

Obesity linked to increased risk of rapid cartilage loss

Washington, July 14 (ANI): A new study has shown that obesity, among other factors, is strongly associated with an increased risk of rapid cartilage loss.

Tibio-femoral cartilage is a flexible connective tissue that covers and protects the bones of the knee. Cartilage damage can occur due to excessive wear and tear, injury, misalignment of the joint or other factors, including osteoarthritis (the most common form of arthritis).

In osteoarthritis, the cartilage breaks down and, in severe cases, can completely wear away, leaving the joint without a cushion. The bones rub together, causing further damage, significant pain and loss of mobility.

The best way to prevent or slow cartilage loss and subsequent disability is to identify risk factors early.

“Osteoarthritis is a slowly progressive disorder, but a minority of patients with hardly any osteoarthritis at first diagnosis exhibit fast disease progression,” said the study’s lead author, Frank W. Roemer, M.D., adjunct associate professor at Boston University and co-director of the Quantitative Imaging Center at the Department of Radiology at Boston University School of Medicine.

“So we set out to identify baseline risk factors that might predict rapid cartilage loss in patients with early knee osteoarthritis or at high risk for the disease,” Dr. Roemer added.

The researchers recruited patients from the Multicenter Osteoarthritis (MOST) Study, a prospective study of 3,026 people, age 50 – 79, at risk for osteoarthritis or with early x-ray evidence of the disease.

Dr. Roemer’s study consisted of 347 knees in 336 patients. The patient group was comprised of 65.2 percent women, mean age 61.2, with a mean BMI of 29.5, which is classified as overweight. Recommended BMI typically ranges from 18.5 to 25. Only knees with minimal or no baseline cartilage damage were included.

Of 347 knees selected for the study, 20.2 percent exhibited slow cartilage loss over the 30-month follow-up period and 5.8 percent showed rapid cartilage loss.

Rapid cartilage loss was defined by a whole organ magnetic imaging score of at least 5, indicating a large full thickness loss of 75 percent in any subregion of the knee during the follow-up period.

The results showed that the top risk factors contributing to rapid cartilage loss were baseline cartilage damage, high BMI, tears or other injury to the meniscus (the cartilage cushion at the knee joint) and severe lesions seen on MRI at the initial exam. Other predictors were synovitis (inflammation of the membrane that lines the joints) and effusion (abnormal build-up of joint fluid).

Excess weight was significantly associated with an increased risk of rapid cartilage loss. No other demographic factors-including age, sex and ethnicity-were associated with rapid cartilage loss.

“As obesity is one of the few established risk factors for osteoarthritis, it is not surprising that obesity may also precede and predict rapid cartilage loss,” Dr. Roemer said.
he study has been published in the August issue of Radiology. (ANI)

Selenium enriched eggs developed in Coimbatore

Coimbatore, July 8 (ANI): A poultry farm in Coimbatore has developed selenium-enriched eggs to counter selenium deficiencies.

The eggs are called ‘super eggs’, which are selenium rich and are capable of curing diseases like arthritis, cancer, diabetes and cardiovascular diseases. These diseases have a common root that is less selenium intake.

Considering this a private egg producer near Palladam has developed these peculiar eggs where hens in layer farms are fed with rich organic selenium fodder, which includes fish, maize and 14 other ingredients.

“We have developed a new kind of an egg called as selenium enriched eggs, which we are able to produce by feeding hens which you see behind, with special diet rich in selenium sources now, the selenium enriched egg not only gives (meets) about your daily selenium requirements. Also, it contains a number of other benefits as well,” said Balaji, proprietor of A Hi -Tech poultry.

According to a research in Scotland University, scientists have identified around 40 diseases related to selenium deficiency.

These eggs are graded and have printed dates on them so that consumers can come to know, how fresh they are. They are even packed nicely, so that it is convenient for consumers to carry them back home.

The poultry farm has a production capacity of five lakh eggs, which are supplied, to Tamil Nadu, Kerala and Karnataka. They also plan to export these eggs to Middle East and other European countries. By Jehovah.G (ANI)

Microscopic ‘beads’ may revolutionise organ transplantation

Washington, July 7 (ANI): If Medical College of Georgia researchers are to be believed, organ transplantation in future may include microscopic beads that create “designer” immune cells so that patients may tolerate their new organ.

Dr. Anatolij Horuzsko, reproductive immunologist at the MCG Center for Molecular Chaperone/Radiobiology and Cancer Virology, has already used this approach successfully in mice with skin grafts.

“It’s absolutely natural,” says the researcher.

The degradable microparticles deliver the most powerful known form of HLA-G, a natural suppressor of the immune response, straight to dendritic cells, which typically show the immune system what to attack.

The microparticles are given right after a transplant, just as dendritic cells are giving the immune system a heads up to get busy attacking the new organ.

Dr. Horuzsko says that microparticle therapy likely would be needed for just a few weeks, until the dendritic cells have learned instead to ignore it.

“It’s like a calming effect and once tolerance is established, we don’t need it any more,” he says.

His team compared the success of HLA-G microparticles with the dendritic cell marker to those without a marker, those with were much more efficient at getting where needed and acting.

He says that those without direction likely were consumed by garbage eaters called macrophages.

“We want to create in kidney transplant patients, the same tolerance to the new kidney,” says Dr. Horuzsko, who reckons that HLA-G microparticles could be doing just that within five years.

He presented the patented process along with his other latest HLA-G findings during an opening lecture of the 5th International Conference on HLA-G in Paris, July 6-8.

Dr. Horuzsko believes that marked microparticles also have treatment potential in diseases where the immune system attacks normal tissue, such as arthritis, multiple sclerosis and inflammatory bowel disease.

He is currently working in collaboration with Dr. Laura Mulloy, chief of the Section of Nephrology, Hypertension and Transplantation Medicine in the MCG School of Medicine, to find out whether higher natural levels of HLA-G already are giving some transplant patients an edge, by comparing HLA-G expression in those who keep and reject their transplanted kidneys. (ANI)

Scientists uncover new trigger for chronic inflammation in rheumatoid arthritis

London, June 29 (ANI): Scientists at Imperial College London say that blocking a signal molecule made by the human body, which triggers the immune system into action, may make it possible to develop more effective treatments for rheumatoid arthritis.

Rheumatoid arthritis is the most common autoimmune disease that causes painful and persistent swelling in the joints, which can result in damage to the bone and cartilage.

Considering that around half of all patients do not respond to one or more of the treatments currently available, the researchers say that stopping the disease closer to the root of the problem could be the best way to treat it.

In their study paper, the researchers point out that the body responds to an infection by a microbe by turning on a molecular switch to set the immune system into action.

They say that their findings show that a signal molecule called tenascin-C can trigger the same molecular switch, and also activate the immune system.

They add that high levels of tenascin-C present in joints, therefore, may cause the activated immune system to attack the joint leading to the persistent inflammation of rheumatoid arthritis.

The researchers also reveal that the molecular switch called TLR4 is found on the surface of immune cells.

According to them, studies conducted in the past have shown that mice without TLR4 do not show chronic joint inflammation.

The team hope that scientists can develop new treatments that target the interaction between tenascin-C and TLR4, which may help to combat rheumatoid arthritis.

“Rheumatoid arthritis is a debilitating and painful disease and, unfortunately, there is no cure. Furthermore, current treatments are not effective for many patients,” Nature magazine quoted Dr. Kim Midwood, lead author of the study from the Kennedy Institute of Rheumatology at Imperial College London, as saying.

“We have uncovered one way that the immune system may be triggered to attack the joints in patients with rheumatoid arthritis. We hope our new findings can be used to develop new therapies that interfere with tenascin-C activation of the immune system and that these will reduce the painful inflammation that is a hallmark of this condition,” added Dr. Midwood.

The authors say that the next step will be to work out the precise mechanism by which tenascin-C increases these levels of inflammatory molecules in the human joint, and to find ways to inhibit this action.

A research article on their findings has been published in the journal Nature Medicine. (ANI)

Donate your computer’s idle time to find cure for HIV, Parkinson’s, breast cancer

Washington, June 21 (ANI): Your computer can be put to good use even when its not in use, for now it’s possible to donate the idle time to cutting-edge biomedical research aimed at finding a cure for HIV, Parkinson’s, arthritis, and breast cancer.

University of Delaware’s “Docking@Home” project, led by Michela Taufer, assistant professor of computer and information sciences, allows people to donate their computer’s idle time to perform scientific calculations that will aid in creating new and improved medicines to thwart these major diseases.

Taufer explained that researchers should create molecular models and simulate their interactions to reveal possible candidates for effective drugs, which could then be put under laboratory testing. And such a simulation is called “docking”.

As there are infinite combinations of molecules and their binding orientations, simulating them requires tremendous computing power.

Supercomputers often have a long waiting line or are too expensive to use for extended periods, said Taufer.

Thus, researchers have turned to citizen volunteers for help, which enables them to distribute the hundreds of thousands of computing tasks across a large number of computers.

Although the research is still in the validation stage, the process is aimed at studying new drugs.

“We are transforming a process in nature into computer steps-an algorithm,” explained Taufer.

To volunteer your computer’s idle time to do scientific calculations, it takes only a few simple steps highlighted on the project Web page (http://docking.cis.udel.edu/).

One can install a free, open-source software program called BOINC (Berkeley Open Infrastructure for Network Computing), developed at the University of California, and link up to the Docking Server at the University of Delaware to become part of the network.

The computer’s idle cycles are accessed automatically when it is not in use.

Currently, the 6,000 volunteers worldwide who currently are involved in UD’s Docking@Home project are contributing to the completion of some 30,000 docking tasks per day, said Taufer. (ANI)

Arthritis drug may help fight flu

Washington, May 27 (ANI): A drug commonly used to treat rheumatoid arthritis has been found to reduce some of the severe symptoms of the Influenza A virus infection, say researchers from University of Maryland.

The study suggests that tempering the response of the body’s immune system to influenza infection may alleviate some of the more severe illness and even reduce mortality from this virus.

The team found that mice infected with the Influenza A virus responded favourably to a drug called Abatacept, which is commonly used to treat people with rheumatoid arthritis.

“We found that treating the mice with Abatacept minimized tissue damage caused by the immune response, but still enabled the body to rid itself of the virus,” said Dr Donna L. Farber, a professor of surgery and microbiology and immunology at the University of Maryland School of Medicine and the study’s senior author.

“The mice didn’t become as sick, recovered much faster and had much less damage to the lungs, compared to mice that weren’t given the drug.

“Moreover, treatment with Abatacept significantly improved survival for mice infected with a lethal dose of influenza virus,” she added.

The treated mice were 80 percent more likely to survive the infection, compared to 50 percent for those who weren’t treated.

“We believe that our findings are very significant because they provide a potential new treatment for infection by the influenza virus – one that would dampen the immune response, yet still preserve its protective effects,” said Dr. Farber.

The study appears in The Journal of Immunology. (ANI)

Kiwi elite umpire Bowden finally breaks his silence

London, May 24 (ANI): Cricket umpire Bowden has become the antithesis of the archetypal man looking down the 22-yard strip, the understated, sober, unnoticed chap in the white coat.

But while he loves the attention, Bowden hates the accompanying media criticism and is desperate to be taken seriously, and not for his antics.

So for three years, he has laboured under the weight of a self-imposed media ban.

He has asked the permission of the International Cricket Council to be interviewed by the Sunday Star-Times, and wanted advance notice of the question topics, to which he has compiled judicious written replies.

Then, over the space of two hours, he happily answered every question anyway, talking about everything from the crisis of faith he suffered when arthritis ruined his cricketing career, to how he sings adapted Michael Jackson lyrics for motivation. And so emerges the other reason for the media ban: Billy Bowden can’t help himself.

Bowden says he was “destined” to become an umpire, although he too admits he would rather have been an international cricketer.

When he was 21, he contracted severe viral arthritis the original reason for his bent fingers curtailing a career he thinks might, with hard work, have culminated in national selection.

Until four years ago, when he became an ambassador for Arthritis New Zealand, he didn’t talk about it publicly.

“Was it because I was embarrassed, because I was a failure, my faith was tested… because it was why, why me?” he says. “I was healthy, only 21, my life was in front of me, and it was an injustice. I wasn’t happy.”

Eventually, his strong Baptist upbringing allowed him to reach a more positive conclusion. “Arthritis has been good for me, because I am sitting here now talking to you about something I would probably never have done if I had been healthy and played cricket. God has got a plan for everyone, and that was my plan… my arthritis has changed my life and turned me into someone I might not have been.”

Twenty-five years, 46 test matches and 132 one-day internationals later, Bowden is the only New Zealand member in a 12-strong world elite panel.

He reckons he spends just 90 nights a year in his own bed. His wife Jenny, a nutritionist who writes a column for the Listener, travels with him only half the time. He leaves the country again on Thursday for the Twenty20 World Cup in England, the day after their third wedding anniversary.

While he’s told his schedule only three months in advance, it’s likely that this year’s schedule alone will include Dubai, England, South Africa (for the ICC Champions Trophy) and perhaps the West Indies.

He agrees that it is, at times, a lonely existence. Then he chirps up.

“I follow the sun, I experience cultures, the different countries, and basically, I do something I love. It can’t get much better than that, can it? Just quietly, I think any criticism that I do get in the papers, on radio or on TV, I just say to myself, that’s OK, I probably had a more fun day than them anyway.”

He once, reportedly, danced around an Auckland pub on South African captain Hansie Cronje’s shoulders and gave the craggy Australian captain Steve Waugh an impromptu hug at the end of his final test (“I think Steve liked it,” he says wryly. “If I saw him now, I’d give him another hug”). So the reality of modern-day cricket must make it even more painful; there’s little socialising between player and official.

“It’s more like business than pleasure now,” he says, “they’ve got their team, we’ve got our team.” Then he adds:

“Unfortunately you can’t be seen in the bar or cafe with them because the next day you might have to make that tough decision and there could be a journo, like you, with a photo.”

Bowden’s like that. A lot of replies, which began life about other topics, slowly meander around to the media, their treatment of him, and his attitude towards them.

He’d contend that his dad is far more obsessed. Marcus Bowden, an 83-year-old retired Baptist minister, is a big fan of his youngest son. “He looks after everything that goes in the paper, good, bad or indifferent, he cuts it out,” says Bowden.

“He might need another house to put it all in. It’s just a hobby.” Bowden tells his dad not to make agitated phone calls to Radio Sport and sports editors.

The media bans, announced to the Dominion Post in 2006 and the Sunday News a year later, were, he says, not arrogance on his part, but about improving his own performance.

Has he ever been hurt about the things that have been written? While he shrugs off how one 2007 survey of Australian players rated him test cricket’s worst umpire, the one that seems to have stung (and he accepts as valid) was when he was widely criticised for openly souveniring match balls and stumps.

This mantra, which he repeats later, appears to have come from Jenny, whom he describes as his “inspiration” and his “hero”. They’ve been together for eight years (he has two children from a previous relationship, daughter Brooke, 19, and son Fraser, 16, who captains Westlake Boys’ cricket team). “My gorgeous wife says `bingo, they are on to it, they are correct, so don’t try to fight it’,” he says. (ANI)

Popular cancer drug rituximab may lead to oft-fatal viral brain infection

Washington, May 19 (ANI): Scientists are concerned that the popular cancer drug, rituximab, may increase a person’s chances of acquiring an often fatal viral brain infection, known as progressive multifocal leukoencephalitis (PML), which attacks the brain’s white matter.

The worries about this possible harmful effect of rituximab emerged after MRI brain scans and biopsies were conducted on a 57-year-old lawyer in New York and an 83-year-old woman in Chicago, both of whom had been taking the drug before they developed the brain infection.

The two patients are currently part of a new study from the Northwestern University Feinberg School of Medicine RADAR project, an international consortium of physicians that collaborate to identify adverse reactions to medications and devices, which is being led by Dr. Charles Bennett.

Knowing more about the suggested link between rituximab and PML is important because, besides its use as a cancer drug, this medicine is also used for treating rheumatoid arthritis, multiple sclerosis, lupus erythematosus and autoimmune anaemias.

Bennett has revealed that, from 1997 to 2008, as many as 57 patients with anemia, rheumatoid arthritis or lymphoma developed the fatal brain disease after taking rituximab.

They died an average of two months after being diagnosed, he said.

“Rituximab is one of the most prominent drugs in a new class called monoclonal antibodies. It’s now the third monoclonal antibody that is associated with PML,” added Bennett.

The researcher points out that the brain infection is often overlooked and undiagnosed because it is so subtle at first.

“People may think it’s early Alzheimer’s disease or depression. Many of these patients have cancer and when they die, people assume it’s the cancer that killed them,” he said.

He admitted that it was yet to be found out how rituximab is connected to the brain virus and who might be at risk.

Bennett said that the study results illustrate a need for caution in prescribing rituximab.

“The drug has tremendous usefulness in lymphoma, but as its use expands to diseases that are not cancer, we might have to reconsider the risk benefit. Some cancer patients take this drug chronically for non-fatal chronic leukemia where the risk-benefit calculations differ from lymphoma,” he said.

He suggested if people on rituximab develop any strange neurological symptoms like forgetfulness, disorientation or mood changes, their doctors should be alerted.

A research article on the study has been published in the journal Blood. (ANI)

Now, a tissue scaffold that regrows cartilage, bone

Washington, May 12 (ANI): In a novel study, MIT scientists have developed a new tissue scaffold that can stimulate bone and cartilage growth when transplanted into the knees and other joints.

Lead researchers Lorna Gibson, of the MIT, and Professor William Bonfield, of Cambridge University, said that the scaffold could offer a potential new treatment for sports injuries and other cartilage damage, such as arthritis.

“If someone had a damaged region in the cartilage, you could remove the cartilage and the bone below it and put our scaffold in the hole,” said Gibson.

The scaffold has two layers, one that mimics bone and one that mimics cartilage. When implanted into a joint, the scaffold can stimulate mesenchymal stem cells in the bone marrow to produce new bone and cartilage.

The technology is currently limited to small defects, using scaffolds roughly 8 mm in diameter.

The study conducted using goats showed that the scaffold successfully stimulated bone and cartilage growth after being implanted in their knees.

Gibson said that the new scaffold could offer a more effective, less expensive, easier and less painful substitute for treating cartilage injuries.

The findings appear in the Journal of Biomedical Materials Research. (ANI)

Women suffer more disability than men during old age

Washington, May 03 (ANI): Although women live longer than men, they suffer more from disability that stems chiefly from obesity and arthritis, says a new study.

In the study, researchers found that the most prevalent cause of suffering and disability in senior women is arthritis and obesity, leading to two and a half times more suffering compared to men in the same age group.

They also found that higher rates of obesity and arthritis among these women explained up to 48 percent of the gender gap in disability – above all other common chronic health conditions.

“While women tend to live longer than men, this study shows that they are at greater risk of living with disability and much of the excess disability is attributable to higher rates of obesity and arthritis,” said Heather Whitson, M.D., assistant professor of medicine and lead investigator of the study presented today at the Annual Scientific Meeting of the American Geriatrics Society.

“This is important because it suggests that women’s tendency to pack on extra pounds in their child-bearing and peri-menopausal years translates into loss of independence in their old age,” Whitson added.

Researchers said the study, which included 5,888 people over 65, is the first to isolate the impact of specific chronic health conditions on the difference in disability rates between older men and women. (ANI)

Women with arthritis more likely to quit job than men

Washington, May 1 (ANI): A new study has shown that women suffering from arthritis are more likely to stop working than men with the same disability.

While men keep working, they are likely to report negative experiences.

The research team led by Simone A. Kaptein of the Toronto Western Research Institute analysed the responses for almost 9,000 individuals between the ages of 25 and 64.

They were asked about the intensity and frequency of activity limitations for activities likely to be encountered in the work place.

The results showed that 2.3 percent of the working-age population had arthritis disability, the second-most frequent cause of disability after back and spine conditions.

More than half of those with arthritis disability reported being out of the labour force, almost 41 percent were unemployed, and 5 percent were unemployed and looking for work.

A higher proportion of women were out of the labour force than men. The study showed that single or previously married women were more likely to be out of the labour force.

“Additional research needs to examine in more detail the specific reasons that men and women give up employment and their relationship to family composition and marital status,” the authors state.

The study was published in the May issue of Arthritis Care and Research. (ANI)